Allergan to Present New Dry Eye Data at the American Academy of Optometry Meeting in Chicago

DUBLIN, Oct. 9, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced several Allergan-supported abstracts were selected for poster presentation at the Annual American Academy of Optometry in Chicago, Illinois from October 11 – 14, 2017.

Building on a nearly 60-year heritage in Eye Care with expertise in discovering and developing new products to preserve and protect vision, these poster presentations further establish Allergan's commitment to helping individuals suffering from Dry Eye Disease.

The scheduled times (noted in local Central Time) of the Allergan poster presentations, presentation titles, locations and authors are as follows:

• Effectiveness and Safety of Intranasal Tear Neurostimulation for Subjects with Dry Eye Disease
• Date and Time: Friday, October 13 10:00 am – 12:00 pm CT
• Location: Board #53, Hall D McComrick Place
• Authors: D. Evans, S. Baba, M. Holdbrook, M. Senchyna and E. Holland

• Effect of Intranasal Neurostimulation on Total Tear Lipid and Total Protein Concentrations in Subjects with Dry Eye
• Date and Time: Friday, October 13 1:00 pm – 3:00 pm CT
• Location: Board #70, Hall D McComrick Place
• Authors: M. Senchyna, K. Green, M. Kamat, A. Woodward, P. Argüeso, S. Baba and M. Holdbrook

• A Comparison of Tear Film Properties in Subjects With Evaporative and Non-Evaporative Dry Eye
• Date and Time: Friday, October 13 1:00 pm – 3:00 PM CT
• Location:  Board #56 Hall D McComrick Place
• Authors: K. Wong, J. Tan, M. Willcox and F. Stapleton

• Lipid Layer Thickness Changes with an Omega-3 Formulated Eye Drop
• Date and Time: Friday, October 13 1:00 pm – 3:00 pm CT
• Location: Board #60, Hall D McComrick Place
• Authors: J. Fogt, M. Kowalski, N. Fogt, P. King-Smith and J. Barr

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      

Allergan:

Investors: 
Daphne Karydas
(862) 261-8006

Media: 
Mark Marmur
(862) 261-7558

Suzanne Jacobson
(201) 273-4724

SOURCE Allergan plc

Related Links

http://www.allergan.com